Literature DB >> 14500219

Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes.

Adam R Henn1, Edward A Levine, William McNulty, Ronald J Zagoria.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the efficacy of percutaneous radiofrequency ablation of hepatic neuroendocrine metastases for symptomatic relief of neuroendocrine syndromes.
CONCLUSION: Percutaneous radiofrequency ablation, a minimally invasive technique, is an effective and safe way to reduce systemic symptoms in patients with hepatic metastases from neuroendocrine neoplasms.

Entities:  

Mesh:

Year:  2003        PMID: 14500219     DOI: 10.2214/ajr.181.4.1811005

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  11 in total

1.  Liver-specific therapies for metastases of neuroendocrine pancreatic tumors.

Authors:  Volker Fendrich; Patrick Michl; Nils Habbe; Detlef Klaus Bartsch
Journal:  World J Hepatol       Date:  2010-10-27

Review 2.  Evolving treatment strategies for management of carcinoid tumors.

Authors:  Jonathan Strosberg
Journal:  Curr Treat Options Oncol       Date:  2013-09

Review 3.  [Radiofrequency ablation of liver metastases].

Authors:  P L Pereira; S Clasen; A Boss; D Schmidt; C Gouttefangeas; C Burkart; J Wiskirchen; G Tepe; C D Claussen
Journal:  Radiologe       Date:  2004-04       Impact factor: 0.635

4.  Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.

Authors:  Jonathan R Strosberg; Aejaz Nasir; Pamela Hodul; Larry Kvols
Journal:  Gastrointest Cancer Res       Date:  2008-05

5.  Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy.

Authors:  Liesbeth M Veenendaal; Inne H M Borel Rinkes; Cornelis J M Lips; Richard van Hillegersberg
Journal:  World J Surg Oncol       Date:  2006-06-26       Impact factor: 2.754

6.  Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases.

Authors:  Liselot B J van Iersel; Ellen J Hoekman; Hans Gelderblom; Alexander L Vahrmeijer; Els L van Persijn van Meerten; Fred G J Tijl; Henk H Hartgrink; Peter J K Kuppen; Johan W R Nortier; Rob A E M Tollenaar; Cornelis J H van de Velde
Journal:  Ann Surg Oncol       Date:  2008-05-10       Impact factor: 5.344

Review 7.  New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.

Authors:  Esther Una Cidon
Journal:  World J Gastrointest Oncol       Date:  2017-01-15

8.  Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up.

Authors:  Suayib Yalcin; Fahri Bayram; Sibel Erdamar; Ozlem Kucuk; Nevin Oruc; Ahmet Coker
Journal:  Arch Med Sci       Date:  2017-01-25       Impact factor: 3.318

Review 9.  Actual role of radiofrequency ablation of liver metastases.

Authors:  Philippe L Pereira
Journal:  Eur Radiol       Date:  2007-02-15       Impact factor: 7.034

10.  The problems of radiofrequency ablation as an approach for advanced unresectable ductal pancreatic carcinoma.

Authors:  Raffaele Pezzilli; Claudio Ricci; Carla Serra; Riccardo Casadei; Francesco Monari; Marielda D'Ambra; Roberto Corinaldesi; Francesco Minni
Journal:  Cancers (Basel)       Date:  2010-07-01       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.